

Prostatype Genomics publishes newsletter on ongoing addition of new customers in USA and Spain

This edition of the company's newsletter focuses on the ongoing commercial scale-up in the United States and Spain. In the US market, practical work is underway to add several urologists for commercial use of the Prostatype® genetic test after the recently announced market entry, and in Spain agreements have been signed with a number of private healthcare providers, of which some have already started to use Prostatype® commercially, following the presentation of strong positive final results from a multicentre study in April.

Content of the newsletter:

CEO Fredrik Rickman on the commercial scale-up in the United States

- After recently announced market entry, the company is now working on the practicalities of adding several urologists for commercial use of Prostatype® as soon as possible.
- Great interest in the company at the globally recognized AUA conference, where strong positive interim results from an ongoing long-term follow-up study with Prostatype® were presented.

Commercial scale-up also in Spain after successful multicentre study

- The company has recently signed agreements with a number of private healthcare providers, of which some have already started to use Prostatype® commercially, and more negotiations are ongoing.
- Strong attention at the annual conference of the Spanish National Urology Association where the study results were presented, including a panel discussion on Prostatype® and most suitable patients.

Research report from Aktiespararna sees great upside in the company's share with a target price of 0.12 SEK

- In a research report by Aktiespararna on April 27, the target price for the company's share is set at SEK 0.12 per with "a large upside compared to today's levels".

The number of new prostate cancer cases is estimated to more than double by 2040 according to the Lancet Commission

- According to a recently published study by the Lancet Commission, the number of new cases per year of prostate cancer is expected to more than double until 2040 due to changing demographics and an increasing life expectancy.

Read the full newsletter and subscribe via this link:

<https://bit.ly/progenjun24en>

Prostatype Genomics' newsletter is published to offer broader and more in-depth information about the company's operations and progress. It is produced together with the IR communications agency Honeybadger, <https://www.honeybadger.se/en/>

Contacts

For further information about Prostatype Genomics, please contact:

Fredrik Rickman (previously Persson), CEO Prostatype Genomics AB

Telephone: +46 (0) 73 049 77 01.

e-mail: fredrik.persson@prostatypegenomics.com

Certified Advisor

Carnegie Investment Bank AB (publ), +46 (0)73 856 42 65, certifiedadviser@carnegie.se

About Us

About Prostatype Genomics AB

Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.